Clinical trial · Observational
Rare Subtypes of Gastrointestinal Cancers
Rare Subtypes of Gastrointestinal Cancers - Real-world Data and Liquid Biopsies
NCT04838327CI-TRIAL-00079539unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A single-arm prospective observational translational study of biomarkers in patients receiving targeted treatment for rare subtypes of cancer of the Gastrointestinal Tract.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Gastrointestinal Tract | Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Feasibility and translational analysis
- timeFrame
- 2 years last patient
- description
- Investigating potential prognostic and predictive markers for efficacy by molecular characteristics and mutational analysis. We seek to describe the prognostic and predictive value of cfDNA, ctDNA and other markers, e.g. evaluate baseline cf- and ctDNA levels, fluctuations of cf- and ctDNA during treatment and follow up.
Secondary outcomes (4)
- measure
- Response rate
- timeFrame
- 6 months post-treatment
- description
- According to RECIST version 1.1
- measure
- Progression Free Survival
- timeFrame
- 2 years last patient
- description
- Time from inclusion to progression according to RECIST version 1.1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of a rare subtype of GI cancer including BRAF V600E mutation, MSI-H, HER2 and others * Diagnosis of cancer of the gastrointestinal tract may be made by histo- or cyto-pathology, or by clinical and imaging criteria * Planned for targeted treatment * Age 18 years or older * Able to understand written information * Consent to samples for translational research Exclusion Criteria: * Conditions precluding translational blood sampling * Another concomitant cancer
References
Publications (0)
Data not yet available
No reference posted for this study.